1
|
Hung LY, Tanaka Y, Herbine K, Pastore C, Singh B, Ferguson A, Vora N, Douglas B, Zullo K, Behrens EM, Li Hui Tan T, Kohanski MA, Bryce P, Lin C, Kambayashi T, Reed DR, Brown BL, Cohen NA, Herbert DR. Cellular context of IL-33 expression dictates impact on anti-helminth immunity. Sci Immunol 2020; 5:5/53/eabc6259. [PMID: 33188058 DOI: 10.1126/sciimmunol.abc6259] [Citation(s) in RCA: 65] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Accepted: 09/28/2020] [Indexed: 12/13/2022]
Abstract
Interleukin-33 (IL-33) is a pleiotropic cytokine that can promote type 2 inflammation but also drives immunoregulation through Foxp3+Treg expansion. How IL-33 is exported from cells to serve this dual role in immunosuppression and inflammation remains unclear. Here, we demonstrate that the biological consequences of IL-33 activity are dictated by its cellular source. Whereas IL-33 derived from epithelial cells stimulates group 2 innate lymphoid cell (ILC2)-driven type 2 immunity and parasite clearance, we report that IL-33 derived from myeloid antigen-presenting cells (APCs) suppresses host-protective inflammatory responses. Conditional deletion of IL-33 in CD11c-expressing cells resulted in lowered numbers of intestinal Foxp3+Treg cells that express the transcription factor GATA3 and the IL-33 receptor ST2, causing elevated IL-5 and IL-13 production and accelerated anti-helminth immunity. We demonstrate that cell-intrinsic IL-33 promoted mouse dendritic cells (DCs) to express the pore-forming protein perforin-2, which may function as a conduit on the plasma membrane facilitating IL-33 export. Lack of perforin-2 in DCs blocked the proliferative expansion of the ST2+Foxp3+Treg subset. We propose that perforin-2 can provide a plasma membrane conduit in DCs that promotes the export of IL-33, contributing to mucosal immunoregulation under steady-state and infectious conditions.
Collapse
Affiliation(s)
- Li-Yin Hung
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Yukinori Tanaka
- Department of Dental Anesthesiology and Pain Management, Tohoku University Hospital, Sendai, Miyagi 980-8574, Japan
| | - Karl Herbine
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Christopher Pastore
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Brenal Singh
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Annabel Ferguson
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Nisha Vora
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Bonnie Douglas
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Kelly Zullo
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Edward M Behrens
- Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Tiffany Li Hui Tan
- Department of Otorhinolaryngology-Head and Neck Surgery, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Michael A Kohanski
- Department of Otorhinolaryngology-Head and Neck Surgery, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Paul Bryce
- Immunology and Inflammation Therapeutic Area, Sanofi US, Cambridge, MA 02319, USA
| | - Cailu Lin
- Monell Chemical Senses Center, Philadelphia, PA 19104, USA
| | - Taku Kambayashi
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | | | - Breann L Brown
- Department of Biochemistry, Center for Structural Biology, Vanderbilt University, Nashville, TN 37232, USA
| | - Noam A Cohen
- Department of Otorhinolaryngology-Head and Neck Surgery, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA 19104, USA.,Monell Chemical Senses Center, Philadelphia, PA 19104, USA.,Michael J. Crescenz Veterans Affairs Medical Center Surgical Service, Philadelphia, PA 19104, USA
| | - De'Broski R Herbert
- Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
| |
Collapse
|
2
|
Belle NM, Ji Y, Herbine K, Wei Y, Park J, Zullo K, Hung LY, Srivatsa S, Young T, Oniskey T, Pastore C, Nieves W, Somsouk M, Herbert DR. TFF3 interacts with LINGO2 to regulate EGFR activation for protection against colitis and gastrointestinal helminths. Nat Commun 2019; 10:4408. [PMID: 31562318 PMCID: PMC6764942 DOI: 10.1038/s41467-019-12315-1] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2018] [Accepted: 08/26/2019] [Indexed: 12/14/2022] Open
Abstract
Intestinal epithelial cells (IEC) have important functions in nutrient absorption, barrier integrity, regeneration, pathogen-sensing, and mucus secretion. Goblet cells are a specialized cell type of IEC that secrete Trefoil factor 3 (TFF3) to regulate mucus viscosity and wound healing, but whether TFF3-responsiveness requires a receptor is unclear. Here, we show that leucine rich repeat receptor and nogo-interacting protein 2 (LINGO2) is essential for TFF3-mediated functions. LINGO2 immunoprecipitates with TFF3, co-localizes with TFF3 on the cell membrane of IEC, and allows TFF3 to block apoptosis. We further show that TFF3-LINGO2 interactions disrupt EGFR-LINGO2 complexes resulting in enhanced EGFR signaling. Excessive basal EGFR activation in Lingo2 deficient mice increases disease severity during colitis and augments immunity against helminth infection. Conversely, TFF3 deficiency reduces helminth immunity. Thus, TFF3-LINGO2 interactions de-repress inhibitory LINGO2-EGFR complexes, allowing TFF3 to drive wound healing and immunity.
Collapse
Affiliation(s)
- Nicole Maloney Belle
- Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19140, USA
| | - Yingbiao Ji
- Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19140, USA
| | - Karl Herbine
- Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19140, USA
| | - Yun Wei
- Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, 94110, USA.,Department of Inflammation and Oncology, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA, 94080, USA
| | - JoonHyung Park
- Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19140, USA
| | - Kelly Zullo
- Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19140, USA
| | - Li-Yin Hung
- Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19140, USA.,Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, 94110, USA
| | - Sriram Srivatsa
- Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19140, USA
| | - Tanner Young
- Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19140, USA
| | - Taylor Oniskey
- Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, 94110, USA
| | - Christopher Pastore
- Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19140, USA
| | - Wildaliz Nieves
- Division of Gastroenterology at ZSFG, University of California, San Francisco, San Francisco, CA, 94110, USA
| | - Ma Somsouk
- Division of Gastroenterology at ZSFG, University of California, San Francisco, San Francisco, CA, 94110, USA
| | - De'Broski R Herbert
- Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, 19140, USA. .,Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, 94110, USA.
| |
Collapse
|
3
|
Zullo K, Ji Y, Wei Y, Herbine K, Maloney N, Cohen R, Pastore C, Somsouk M, Srivatsa S, Hung LY, Kohanski M, Cohen N, Herbert D. Lingo3 interacts with TFF2 to control mucosal integrity, Type 1 inflammation, and colitic tissue repair. The Journal of Immunology 2019. [DOI: 10.4049/jimmunol.202.supp.192.8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Constant exposure of intestinal epithelial cells (IEC) to potentially damaging stimuli makes mucosal repair programs essential for gut homeostasis, immunological quiescence and resistance to colitis. Trefoil factor 2 (TFF2) is a mucus associated protein that promotes epithelial barrier integrity in the lung and intestine, but whether a bona-fide TFF2 receptor exists remains controversial. Herein, we provide evidence that leucine rich repeat nogo interacting protein 3 (LINGO3) is a transmembrane component of TFF2 signaling and proliferation within IEC. TFF2 requires LINGO3 for barrier recovery in scratch-wound assays and mice lacking LINGO3 (LINGO3KO) have impaired intestinal barrier function under steady state conditions. Interestingly, LINGO3KO mice phenocopy TFF2KO mice, with both having a significant accumulation of mucosal CD4+TH1 cells expressing IFNg+ TNFa+ under steady-state conditions and impaired recovery from DSS-induced colitis. Impaired recovery in LINGO3KO animals was marked by reduced intestinal crypt regeneration and reduced expression of the stem cell marker LGR5 compared to WT counterparts. Additionally, TFF2 agonist administration (TFF2-Fc) promoted enhanced recovery and limited inflammatory cell recruitment in WT mice during DSS-induced colitis whereas TFF2-Fc treatment was ineffective in LINGO3KO animals. Combined, these data support our contention that a TFF2-LINGO3 ligand/receptor axis regulates tissue repair and inflammation within the gastrointestinal tract through regulation of IEC function.
Collapse
Affiliation(s)
| | | | - Yun Wei
- 2Univ. of California, San Francisco
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Amengual JE, Prabhu SA, Lombardo M, Zullo K, Johannet PM, Gonzalez Y, Scotto L, Serrano XJ, Wei Y, Duong J, Nandakumar R, Cremers S, Verma A, Elemento O, O'Connor OA. Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib. Clin Cancer Res 2017; 23:3084-3096. [PMID: 27993968 PMCID: PMC5474138 DOI: 10.1158/1078-0432.ccr-16-2022] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2016] [Revised: 11/22/2016] [Accepted: 11/23/2016] [Indexed: 12/31/2022]
Abstract
Purpose: Pan-class I/II histone deacetylase (HDAC) inhibitors are effective treatments for select lymphomas. Isoform-selective HDAC inhibitors are emerging as potentially more targeted agents. ACY-1215 (ricolinostat) is a first-in-class selective HDAC6 inhibitor. To better understand the discrete function of HDAC6 and its role in lymphoma, we developed a lymphoma cell line resistant to ACY-1215.Experimental Design: The diffuse large B-cell lymphoma cell line OCI-Ly10 was exposed to increasing concentrations of ACY-1215 over an extended period of time, leading to the development of a resistant cell line. Gene expression profiling (GEP) was performed to investigate differentially expressed genes. Combination studies of ACY-1215 and ibrutinib were performed in cell lines, primary human lymphoma tissue, and a xenograft mouse model.Results: Systematic incremental increases in drug exposure led to the development of distinct resistant cell lines with IC50 values 10- to 20-fold greater than that for parental lines. GEP revealed upregulation of MAPK10, HELIOS, HDAC9, and FYN, as well as downregulation of SH3BP5 and LCK. Gene-set enrichment analysis (GSEA) revealed modulation of the BTK pathway. Ibrutinib was found to be synergistic with ACY-1215 in cell lines as well as in 3 primary patient samples of lymphoma. In vivo confirmation of antitumor synergy was demonstrated with a xenograft of DLBCL.Conclusions: The development of this ACY-1215-resistant cell line has provided valuable insights into the mechanistic role of HDAC6 in lymphoma and offered a novel method to identify rational synergistic drug combinations. Translation of these findings to the clinic is underway. Clin Cancer Res; 23(12); 3084-96. ©2016 AACR.
Collapse
Affiliation(s)
- Jennifer E Amengual
- Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York.
| | - Sathyen A Prabhu
- Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York
| | - Maximilian Lombardo
- Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York
| | - Kelly Zullo
- Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York
| | - Paul M Johannet
- Stanford University School of Medicine, Stanford, California
| | - Yulissa Gonzalez
- Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York
| | - Luigi Scotto
- Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York
| | - Xavier Jirau Serrano
- Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York
| | - Ying Wei
- Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York
| | - Jimmy Duong
- Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York
| | - Renu Nandakumar
- Division of Clinical Pathology, Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York
| | - Serge Cremers
- Division of Clinical Pathology, Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York
| | - Akanksha Verma
- Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York
| | - Olivier Elemento
- Institute for Computational Biomedicine, Weill Cornell Medical College, New York, New York
| | - Owen A O'Connor
- Center for Lymphoid Malignancies, Columbia University Medical Center, New York, New York
| |
Collapse
|
5
|
Amengual JE, Johannet P, Lombardo M, Zullo K, Hoehn D, Bhagat G, Scotto L, Jirau-Serrano X, Radeski D, Heinen J, Jiang H, Cremers S, Zhang Y, Jones S, O'Connor OA. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. Clin Cancer Res 2015; 21:4663-75. [PMID: 26116270 DOI: 10.1158/1078-0432.ccr-14-3068] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Accepted: 06/12/2015] [Indexed: 01/25/2023]
Abstract
PURPOSE Pan-class histone deacetylase (HDAC) inhibitors are effective treatments for select lymphomas. Isoform-selective HDAC inhibitors are emerging as potentially more targeted agents. HDAC6 is a class IIb deacetylase that facilitates misfolded protein transport to the aggresome for degradation. We investigated the mechanism and therapeutic impact of the selective HDAC6 inhibitor ACY-1215 alone and in combination with bortezomib in preclinical models of lymphoma. EXPERIMENTAL DESIGN Concentration-effect relationships were defined for ACY-1215 across 16 lymphoma cell lines and for synergy with bortezomib. Mechanism was interrogated by immunoblot and flow cytometry. An in vivo xenograft model of DLBCL was used to confirm in vitro findings. A collection of primary lymphoma samples were surveyed for markers of the unfolded protein response (UPR). RESULTS Concentration-effect relationships defined maximal cytotoxicity at 48 hours with IC50 values ranging from 0.9 to 4.7 μmol/L. Strong synergy was observed in combination with bortezomib. Treatment with ACY-1215 led to inhibition of the aggresome evidenced by acetylated α-tubulin and accumulated polyubiquitinated proteins and upregulation of the UPR. All pharmacodynamic effects were enhanced with the addition of bortezomib. Findings were validated in vivo where mice treated with the combination demonstrated significant tumor growth delay and prolonged overall survival. Evaluation of a collection of primary lymphoma samples for markers of the UPR revealed increased HDAC6, GRP78, and XBP-1 expression as compared with reactive lymphoid tissue. CONCLUSIONS These data are the first results to demonstrate that dual targeting of protein degradation pathways represents an innovative and rational approach for the treatment of lymphoma.
Collapse
Affiliation(s)
- Jennifer E Amengual
- Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, New York.
| | - Paul Johannet
- Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, New York
| | - Maximilian Lombardo
- Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, New York
| | - Kelly Zullo
- Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, New York
| | - Daniela Hoehn
- Division of Hematopathology, Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York
| | - Govind Bhagat
- Division of Hematopathology, Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York
| | - Luigi Scotto
- Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, New York
| | - Xavier Jirau-Serrano
- Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, New York
| | - Dejan Radeski
- Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, New York
| | - Jennifer Heinen
- Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, New York
| | - Hongfeng Jiang
- Division of Clinical Pathology, Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York
| | - Serge Cremers
- Division of Clinical Pathology, Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York
| | - Yuan Zhang
- Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York
| | - Simon Jones
- Acetylon Pharmaceuticals, Inc., Boston, Massachusetts
| | - Owen A O'Connor
- Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center, New York, New York
| |
Collapse
|
6
|
|
7
|
Abstract
Mantle cell lymphoma (MCL), an aggressive, heterogeneous B-cell lymphoma associated with a relatively short survival has been challenging to study in the laboratory due to the lack of in vitro and in vivo models that accurately recapitulate the disease. Advancement has been made in the characterization of MCL cell lines through the generation of the ATCC MCL bank, enabling their use in xenograft murine models. These models provide valuable but limited information for the preclinical evaluation and development of targeted therapies for MCL despite their deficiencies of a functioning immune system and correct micro-environment. Currently, there is only one double transgenic murine model known to develop spontaneous MCL. There is an urgency to develop innovative transgenic murine models that could be used to better predict therapeutic responses and precisely decipher mechanisms of action, to foster refinement of novel therapeutics for mantle cell lymphoma.
Collapse
Affiliation(s)
- Kelly Zullo
- Center for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center and New York Presbyterian Hospital, New York, NY 10032, USA
| | | | | | | |
Collapse
|